Related Experiment Videos
In vivo antitumor activity demonstrated with squamous carcinoma reactive monoclonal antibody-Vinca immunoconjugates
D A Johnson1, J L Zimmermann, B C Laguzza
1Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, In 46285.
Abstract:
An immunoconjugate (PF1/D-DAVLBHYD), made with the squamous carcinoma reactive monoclonal antibody PF1/D and a derivative of vinblastine, DAVLBHYD, was shown to suppress established T222 human tumor nude mouse xenografts using a multidose protocol. Treatments of xenograft-bearing mice with free drug, free antibody, or a mixture of the two, were unsuccessful at achieving suppression without associated toxicity, using otherwise identical protocols. A Vinca conjugate with a related squamous carcinoma reactive monoclonal antibody, PF1/B, was shown to have similar tumor suppressive activity. In a dual immunoconjugate therapy protocol, PF1/D-DAVLBHYD and PF1/B-DAVLBHYD had additive antitumor effects which were consistent with their complementary tumor reactivity.
Insights
Squamous carcinoma immunoconjugates, PF1/D-DAVLBHYD and PF1/B-DAVLBHYD, suppressed established tumors in mice. This targeted therapy showed additive antitumor effects without toxicity, unlike free drug or antibody treatments.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- Monoclonal antibodies targeting specific cancer antigens offer potential for targeted drug delivery.
- Vinblastine derivatives are potent cytotoxic agents used in chemotherapy.
- Immunoconjugates combine antibody-mediated targeting with drug payload for enhanced efficacy and reduced systemic toxicity.
Purpose of the Study:
- To evaluate the efficacy of PF1/D-DAVLBHYD, an immunoconjugate targeting squamous carcinoma, in suppressing established human tumor xenografts in mice.
- To compare the antitumor activity and toxicity of the immunoconjugate with free drug, free antibody, and a mixture of both.
- To assess the combined therapeutic effect of two distinct squamous carcinoma-reactive immunoconjugates, PF1/D-DAVLBHYD and PF1/B-DAVLBHYD.
Main Methods:
- Development of immunoconjugates using squamous carcinoma-reactive monoclonal antibodies (PF1/D, PF1/B) and a vinblastine derivative (DAVLBHYD).
- Administration of immunoconjugates, free drug, free antibody, or a combination to mice bearing established T222 human tumor xenografts using a multidose protocol.
- Assessment of tumor suppression and associated toxicity in treated mice.
Main Results:
- PF1/D-DAVLBHYD demonstrated significant suppression of established T222 human tumor xenografts in nude mice.
- Treatments with free drug, free antibody, or a mixture of both resulted in toxicity without achieving tumor suppression.
- A related Vinca conjugate, PF1/B-DAVLBHYD, exhibited similar tumor suppressive activity.
- A dual immunoconjugate therapy protocol using PF1/D-DAVLBHYD and PF1/B-DAVLBHYD showed additive antitumor effects.
Conclusions:
- Immunoconjugates like PF1/D-DAVLBHYD offer a promising strategy for targeted cancer therapy, effectively suppressing established tumors.
- Targeted delivery of cytotoxic agents via immunoconjugates can achieve therapeutic effects without the systemic toxicity associated with free drugs.
- Complementary targeting by dual immunoconjugates can lead to additive antitumor effects, enhancing therapeutic outcomes in squamous carcinoma treatment.